Skip to content

Factors Influencing Morbi-mortality in Right Anterior Minithoracotomy Approch for Aortic Valve Replacement

Factors Influencing Morbi-mortality in Right Anterior Minithoracotomy Approch for Aortic Valve Replacement Operated at Dijon University Hospital

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04455165
Acronym
RVAOMITAVA
Enrollment
300
Registered
2020-07-02
Start date
2020-06-29
Completion date
2020-06-29
Last updated
2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Disease

Brief summary

Since 2009, positive experiences with right anterior minithoracotomy as an approach to aortic valve replacement are extensively practiced in our institution. The primary disease process for which patients are referred remains aortic stenosis. But more and more, we met older patients with both aortic stenosis and other cardiac pathology (coronary artery disease, other valvulopathy...). Even if minimally invasive valve surgery has been demonstrated to significantly improve postoperative course (reduced blood transfusion, pain, hospital lengths of stay) and to enhance postoperative recovery, when compared with a median sternotomy, it is however important to have medical data and statistics in order to better understand the factors influencing morbi-mortality and thereby to continue this improvement.

Interventions

PROCEDUREAortic valve replacement

Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)

Sponsors

Centre Hospitalier La Chartreuse
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patients \> 18 y-o who underwent aortic valve replacement

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
30 days mortality incidence rates30 daysMortality from aortic valve replacement to 30 days post-surgery

Secondary

MeasureTime frameDescription
30 days morbidity incidence rates30 daysMorbidity from aortic valve replacement to 30 days post-surgery (major adverse cardiac events)
Long-term morbimortality incidence rates10 yearsMorbimortality from aortic valve replacement up to 10 years post-surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026